In vivo xenograft study and ex vivo treatment of T-PLL primary samples vs healthy control samples. (A) Xenograft study indicating tumor volumes at day 0 and day 7 of NRG-mice engrafted with MyLa cells and treated with a vehicle control, adavosertib, ruxolitinib, or the combination of adavosertib and ruxolitinib. (B) Normalized viability measurement of 13 T-PLL primary samples and 3 healthy control samples after 72-hour single drug and combination treatment shows significant decreases in viability through combination treatment selectively in the T-PLL samples. Cell viability was measured with RealTime-Glo MT Cell Viability Assay and normalized to a DMSO-treated control. Significance was assessed with 1-way ANOVA after Tukey correction. ∗P ≤ .05, ∗∗P ≤ .01, ∗∗∗P ≤ .001, ∗∗∗∗P ≤ .0001. A, adavosertib; R, ruxolitinib; Z, ZN-C3.
Figure 7.

In vivo xenograft study and ex vivo treatment of T-PLL primary samples vs healthy control samples. (A) Xenograft study indicating tumor volumes at day 0 and day 7 of NRG-mice engrafted with MyLa cells and treated with a vehicle control, adavosertib, ruxolitinib, or the combination of adavosertib and ruxolitinib. (B) Normalized viability measurement of 13 T-PLL primary samples and 3 healthy control samples after 72-hour single drug and combination treatment shows significant decreases in viability through combination treatment selectively in the T-PLL samples. Cell viability was measured with RealTime-Glo MT Cell Viability Assay and normalized to a DMSO-treated control. Significance was assessed with 1-way ANOVA after Tukey correction. ∗P ≤ .05, ∗∗P ≤ .01, ∗∗∗P ≤ .001, ∗∗∗∗P ≤ .0001. A, adavosertib; R, ruxolitinib; Z, ZN-C3.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal